Clinical Trials | February 28, 2026
Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Reaffirms Lupin’s commitment to sustainable resource management
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
PICCOLO trial met its primary endpoint of objective response rate (ORR)
The company's sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Subscribe To Our Newsletter & Stay Updated
